Literature DB >> 30641516

Secondary and Tertiary Hyperparathyroidism.

Piergiorgio Messa, Carlo Maria Alfieri.   

Abstract

Secondary hyperparathyroidism (SHP) is a frequent complication of kidney diseases. At variance with all the other forms of SHP, which are compensatory conditions, renal SHP has many pathogenetic peculiarities, which have been only in part defined. Furthermore, in the long course of chronic kidney diseases (CKD), SHP sometimes transforms into a hypercalcemic condition resembling the autonomous form of hyperparathyroidism (tertiary hyperparathyroidism; THP). The clinical consequences of SHP in CKD patients are manifold, encompassing not only bone and mineral disorders, but also other metabolic and organic changes which frequently burden these patients. Although the medical therapeutic tools have substantially increased in number and improved in their efficacy in recent decades, we have as yet no demonstration of a clear benefit regarding the major clinical outcomes. Furthermore, some of these patients, particularly when the autonomous THP develops, still require a surgical approach.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2018        PMID: 30641516     DOI: 10.1159/000491041

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  9 in total

1.  An 8-month-old infant with hypercalcemia and hyperphosphatemia-Answers.

Authors:  Oğuz Özler; Gül Yeşiltepe Mutlu; Mehmet Taşdemir; Şahin Avcı; Ilmay Bilge; Şükrü Hatun
Journal:  Pediatr Nephrol       Date:  2020-06-25       Impact factor: 3.714

2.  Klotho/FGF23 and Wnt in SHPT associated with CKD via regulating miR-29a.

Authors:  Qing Wu; Weifeng Fan; Xiaojing Zhong; Lihong Zhang; Jianying Niu; Yong Gu
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  PTH induces bone loss via microbial-dependent expansion of intestinal TNF+ T cells and Th17 cells.

Authors:  Mingcan Yu; Abdul Malik Tyagi; Jau-Yi Li; Jonathan Adams; Timothy L Denning; M Neale Weitzmann; Rheinallt M Jones; Roberto Pacifici
Journal:  Nat Commun       Date:  2020-01-24       Impact factor: 14.919

4.  Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits.

Authors:  Xiu Chen; Feng Zhao; Wei-Juan Pan; Jia-Mei Di; Wei-Nan Xie; Ling Yuan; Zhi Liu
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

Review 5.  Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects.

Authors:  Paolo Molinari; Carlo Maria Alfieri; Deborah Mattinzoli; Mariarosaria Campise; Angela Cervesato; Silvia Malvica; Evaldo Favi; Piergiorgio Messa; Giuseppe Castellano
Journal:  Front Med (Lausanne)       Date:  2022-03-10

Review 6.  Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D.

Authors:  Mario Cozzolino; Paola Minghetti; Pierluigi Navarra
Journal:  J Nephrol       Date:  2021-10-09       Impact factor: 3.902

7.  Prediction Model of Postoperative Severe Hypocalcemia in Patients with Secondary Hyperparathyroidism Based on Logistic Regression and XGBoost Algorithm.

Authors:  Chao Ding; Yuwen Guo; Qinqin Mo; Jin Ma
Journal:  Comput Math Methods Med       Date:  2022-07-25       Impact factor: 2.809

8.  Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis.

Authors:  Josep Darbà; Alicia Marsà
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

9.  Bilio-pancreatic diversion: report of a case involving bone metabolism complications.

Authors:  Lidia Santarpia; Enza Speranza; Maria Laura Santopaolo; Maurizio Marra; Fabrizio Pasanisi
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.